RATIONALE Intravenous thrombolysis with recombinant tissue Plasminogen Activator improves outcomes in patients treated early after stroke but at the risk of causing intracranial hemorrhage. Restricting recombinant tissue Plasminogen Activator use to patients with evidence of still salvageable tissue, or with definite arterial occlusion, might help reduce risk, increase benefit and identify pati...

The primary hypothesis of this report is that the formation and subsequent removal of fibrin in specific tissues during pathologic processes reflects temporal changes in the local expression of key procoagulant and fibrinolytic genes. To begin to test this hypothesis, we have used quantitative PCR assays and in situ hybridization analysis to examine the effects of endotoxin on the expression of...

Peripheral blood cell preparation from 23 normal subjects and 72 patients with acute and 32 patients with chronic myeloid leukemia were cultured in vitro and released plasminogen activators were analyzed. The quantity of plasminogen activator secreted by leukemic cells varied widely and could not be correlated with the clinical severity of the disease. Immunochemical and electrophoretic techniq...

Tissue Plasminogen Activator 7351C/T Polymorphism and Lacunar Stroke To the Editor: Jannes et al1 reported that a polymorphism in the tissue plasminogen activator (tPA) gene ( 7351C/T) was associated with ischemic stroke in an Australian population. Stratification for stroke subtype demonstrated an association with lacunar infarction (OR: 2.7; 95% CI, 1.1 to 6.7), but not with other stroke subt...

Vitronectin endows plasminogen activator inhibitor 1 (PAI-1), the fast-acting inhibitor of both tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), with additional thrombin inhibitory properties. In view of the apparent association between PAI-1 and vitronectin in the endothelial cell matrix (ECM), we analyzed the interaction between PAI-1 and thrombin in t...

BACKGROUND Neuroendovascular therapy is a common treatment for patients with acute ischemic stroke of the anterior circulation who fail to respond to recombinant tissue plasminogen activator. However, although most hospitals can provide recombinant tissue plasminogen activator therapy, many cannot perform neuroendovascular therapy. Thus, use of a drip-and-ship treatment-liaison system allowing ...

Background: Treatment with tissue plasminogen activator (TPA) for acute stroke requires intensive care of the patient. The risk thrombolytic therapy and need rapid interventions make it clear that nursing role during this time is crucial. aim: This study aims to assess nurses' Performance regarding monitoring patients during administration Tissue Plasminogen Activator drug. Study design...

The fibrinolytic pathway maintains vascular patency by the proteolytic degradation of fibrin, the end-product of coagulation. Formation of a fibrin mesh during haemostasis is part of the physiological response to vascular injury, whereas thrombosis is a pathological obstruction of blood flow, but the biochemical and cellular participants are believed to be similar. Physiological fibrinolysis is...

The effect of thrombin on the release of tissue plasminogen activator from endothelial cells was studied in primary cultures of human umbilical vein endothelial cells. Tissue plasminogen activator concentration in conditioned medium was measured by a two-site radioimmunometric assay. The addition of increasing concentrations (0.01 to 10 U/ml) of thrombin to confluent cultures produced a saturab...

Tissue Plasminogen Activator 7351C/T Polymorphism and Lacunar Stroke To the Editor: Jannes et al1 reported that a polymorphism in the tissue plasminogen activator (tPA) gene ( 7351C/T) was associated with ischemic stroke in an Australian population. Stratification for stroke subtype demonstrated an association with lacunar infarction (OR: 2.7; 95% CI, 1.1 to 6.7), but not with other stroke subt...